Why scientists changed a tanning drug
PT-141 came from work on a tanning drug
You'll see what PT-141 changed, where approval ends, and which harms could affect you, your plans, and your day.
Why did scientists make this drug?
Researchers first made PT-141 while studying a tanning drug. They wanted to keep its unexpected sexual effects. The later medicine is called bremelanotide.
PT-141 works in your brain, not by opening blood vessels. It attaches to a receptor, which is a receiving point on a brain cell. That contact sends messages tied to desire and hunger.
In 2019, FDA approved one narrow use. The approval is for some women distressed by low desire. Those women haven't gone through menopause.
No other use has FDA approval. That includes men, weight loss, and sexual "performance." Read the PT-141 effects, then take your health questions to your doctor.
Keep two questions in mind. Did women feel enough change to matter, and what went wrong? Those answers can guide your choice.
What is PT-141 made from?
PT-141 copies a hormone, a body chemical that carries messages [1]. Scientists changed the copy so it would last longer. The drug contains seven amino acids, bits your body uses to make proteins [7].
PT-141 mainly attaches to two kinds of receptor on brain cells [1]. A receptor is the point where a cell receives a message [1]. The message may then change sexual desire.
Early work found erections in both rats and monkeys after PT-141. Desire-linked brain cells also became active [1]. Small studies later found erection effects in men.
That early work didn't set the approved use. FDA later limited approval to certain women. The PT-141 FDA approval page tells you which women.
For your body, the key is simple. The drug triggers a brain message. It doesn't directly open blood vessels.
Does the drug change desire or blood flow?
Sildenafil belongs to the PDE-5 group of erection pills. These drugs loosen blood-vessel muscle. Blood can then flow into the penis more easily. PT-141 begins in the brain instead [1].
Researchers tested PT-141 in 31 women with troubling low desire. None had reached menopause. Each woman received one dose.
For as long as 24 hours, the women said desire was higher [5]. Their scans showed two brain areas working more closely while they looked at sexual pictures. The scans didn't show whether that change helped them.
This small study shows the change began there. The study can't prove that you'd feel better. It also can't tell how strong your response might be.
Your real question stays the same. Would more desire improve your life? A brain scan can't settle that question for you.
What did the newest studies find?
In 2025, female hamsters received PT-141. The drug didn't make mating seem more rewarding [6]. That result won't tell you what to expect.
In 2024, PT-141 slowed brain-cancer cells in a dish [13]. No person received cancer care in that test. The finding doesn't show that the drug treats cancer.
In 2025, papers placed PT-141 beside other treatments [14][15][16]. Those choices included flibanserin, another drug for women's low desire, and testosterone, a hormone. The papers didn't show that the drug was the clear winner.
Keep each study in its proper place. A hamster isn't a person. Cells in a dish aren't proof of cancer care.
What help can you get here?
PT-141 Telehealth isn't a clinic. It offers no visits, prescriptions, or drugs. These pages only explain published work.
Each PT-141 study report tells you who took part. It also says what changed and what didn't. You'll know whether a finding came from animals or people.
The numbered notes lead to named papers. Possible gains sit beside known harms. Open PT-141 effects or the PT-141 references.
Use a paper to check any broad claim. Your doctor can compare the finding with your health. These pages won't make your choice.
Which harms may disrupt your day?
Start with nausea. Blood pressure shifts and lasting skin color matter too. The PT-141 effects and safety brief explains each risk.